实验室高通量SARS-CoV-2抗原检测方法的评估
在公共检测中心对447人采集鼻拭子和鼻咽拭子,鼻拭子用CoV2Ag检测,鼻咽拭子用RT-PCR检测;另分析9046份医院筛查拭子,阳性CoV2Ag结果用NAT确认。CoV2Ag灵敏度88.5%、特异度99.5%,Ct<30和<25时灵敏度分别升至93.7%和98.7%;9046份筛查中21份(0.2%)为假阳性。
要点
- 基于灭活保存液的实验室高通量CoV2Ag检测鼻拭子具有高特异度和高灵敏度。
- Ct值<30和<25时灵敏度分别达93.7%和98.7%。
- 低流行区建议对阳性CoV2Ag结果用SARS-CoV-2-RNA检测确认。
核心结论
- 使用含灭活保存液的样本管,实验室高通量CoV2Ag检测鼻拭子对SARS-CoV-2抗原(包括B1.1.529变异株)具有很高特异度和高灵敏度。
- 在低流行环境中建议对阳性CoV2Ag结果进行SARS-CoV-2-RNA检测确认。
研究设计与样本
- 在公共检测中心对447人同时采集前鼻拭子和鼻咽拭子,鼻拭子置于灭活保存液用CoV2Ag检测,鼻咽拭子用RT-PCR检测。
- 另分析9046份三级医院筛查拭子的CoV2Ag结果,阳性结果用NAT确认。
主要发现
- 447名公共检测中心参与者中234/447(52.3%)SARS-CoV-2-RNA阳性,研究期间B1.1.529谱系占优势。
- CoV2Ag检测灵敏度为88.5%(95%CI:83.7-91.9%),特异度为99.5%(97.4-99.9%)。
- Ct值<30的拭子灵敏度升至93.7%(97.4-99.9%),Ct值<25时升至98.7%(97.4-99.9%)。
- 9046份住院患者CoV2Ag筛查中,21份(0.2%)拭子经确认NAT判定为假阳性。
关键数值与推荐
- CoV2Ag灵敏度88.5%(95%CI:83.7-91.9%),特异度99.5%(97.4-99.9%)。
- Ct<30时灵敏度93.7%,Ct<25时灵敏度98.7%(95%CI均为97.4-99.9%)。
- 9046份筛查中假阳性21份(0.2%)。
临床怎么用
- 可使用含灭活保存液的样本管进行实验室高通量CoV2Ag鼻拭子检测。
- 在低流行区对阳性CoV2Ag结果用SARS-CoV-2-RNA检测确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antigen tests are an essential part of SARS-CoV-2 testing strategies. Rapid antigen tests are easy to use but less sensitive compared to nucleic acid amplification tests (NAT) and less suitable for large-scale testing. In contrast, laboratory-based antigen tests are suitable for high-throughput immunoanalyzers. Here we evaluated the diagnostic performance of the laboratory-based Siemens Healthineers SARS-CoV-2 Antigen (CoV2Ag) assay. METHODS: In a public test center, from 447 individuals anterior nasal swab specimens as well as nasopharyngeal swab specimens were collected. The nasal swab specimens were collected in sample inactivation medium and measured using the CoV2Ag assay. The nasopharyngeal swab specimens were measured by RT-PCR. Additionally, 9,046 swab specimens obtained for screening purposes in a tertiary care hospital were analyzed and positive CoV2Ag results confirmed by NAT. RESULTS: In total, 234/447 (52.3%) participants of the public test center were positive for SARS-CoV-2-RNA. Viral lineage B1.1.529 was dominant during the study. Sensitivity and specificity of the CoV2Ag assay were 88.5% (95%CI: 83.7-91.9%) and 99.5% (97.4-99.9%), respectively. Sensitivity increased to 93.7% (97.4-99.9%) and 98.7% (97.4-99.9%) for swab specimens with cycle threshold values <30 and <25, respectively. Out of 9,046 CoV2Ag screening tests from hospitalized patients, 21 (0.2%) swab specimens were determined as false-positive by confirmatory NAT. CONCLUSIONS: Using sample tubes containing inactivation medium the laboratory-based high-throughput CoV2Ag assay is a very specific and highly sensitive assay for detection of SARS-CoV-2 antigen in nasal swab specimens including the B1.1.529 variant. In low prevalence settings confirmation of positive CoV2Ag results by SARS-CoV-2-RNA testing is recommended.
引用
- Hörber S, Drees C, Ganzenmueller T, et al. Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay. Clin Chem Lab Med. 2022. PMID: 35700973. doi:10.1515/cclm-2022-0360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。